Agency Forms Undergoing Paperwork Reduction Act Review, 52694-52695 [2016-18837]
Download as PDF
52694
Federal Register / Vol. 81, No. 153 / Tuesday, August 9, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–16–16AVM; Docket No. CDC–2016–
0065]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period;
Withdrawal.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the
withdrawal of the notice published
under the same title on July 26, 2016 for
public comment.
DATES: Effective August 9, 2016.
FOR FURTHER INFORMATION CONTACT:
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: On July
26, 2016 CDC published a notice in the
Federal Register titled ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’ (81
FR 48799). This notice with Federal
Register Document 2016–17601 and
Docket number CDC–2016–0065, was
published prematurely and
inadvertently. The notice is being
withdrawn immediately for public
comment. A new notice will be
published at a later date for public
comment.
SUMMARY:
Jeffrey M. Zirger,
Acting Chief, Information Collection Review
Office, Health Scientist, Office of Scientific
Integrity, Office of the Associate Director for
Science, Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2016–18866 Filed 8–8–16; 8:45 am]
BILLING CODE 4163–18–P
asabaliauskas on DSK3SPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–16AFR]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
VerDate Sep<11>2014
20:00 Aug 08, 2016
Jkt 238001
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Emergency Operations Center (EOC)
Clinical Inquiries Database—New—
Office of Public Health Preparedness
and Response (OPHPR), Centers for
Disease Control and Prevention (CDC)
Background and Brief Description
In May 2015, the Pan American
Health Organization (PAHO) issued an
alert regarding the first confirmed Zika
virus infections in Brazil. Since then,
CDC has been responding to increased
reports of Zika and has assisted in
investigations with PAHO and the
Brazil Ministry of Health. The first
regional travel notices for Zika in South
America and Mexico were posted in
December 2015. In December 2015, the
Commonwealth of Puerto Rico, a United
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
States territory, reported its first
confirmed locally transmitted Zika virus
case. Cases of local transmission have
recently been confirmed in two other
U.S. territories, the United States Virgin
Islands and American Samoa. As of
April 6, 2016, U.S. territories had
reported 351 locally acquired Zika cases
and 3 travel-associated Zika cases to
CDC. Of the 354 cases reported, 37 were
in pregnant women. Zika has not been
spread by mosquitoes in the continental
United States. However, lab tests have
confirmed Zika virus in travelers
returning to the United States. These
travelers have gotten the virus from
mosquito bites and a few non-travelers
got Zika through sex. With the recent
outbreaks in the Americas, the number
of Zika cases among travelers visiting or
returning to the United States is
increasing. CDC monitors and reports to
the public cases of Zika, which will
help improve our understanding of how
and where Zika is spreading.
Zika virus is spread to people
primarily through the bite of an infected
Aedes species mosquito (A. aegypti and
A. albopictus). Mosquitoes that spread
Zika virus are aggressive daytime biters,
but they can also bite at night. A
pregnant woman can pass Zika virus to
her fetus during pregnancy. CDC is
studying how Zika affects pregnancies.
Zika is linked to microcephaly, a severe
birth defect that is a sign of incomplete
brain development. Microcephaly is a
condition where a baby’s head is much
smaller than expected. During
pregnancy, a baby’s head grows because
the baby’s brain grows. Microcephaly
can occur because a baby’s brain has not
developed properly during pregnancy or
has stopped growing after birth.
In February and March 2016, CDC
used OMB emergency clearance
procedures to initiate and expedite
multiple urgently needed information
collections in American Samoa, Puerto
Rico, Brazil, and domestically within
state, tribal, local, and territorial (STLT)
jurisdictions. These procedures have
allowed the agency to target and refine
public health interventions to arrest
ongoing spread of infection.
With this notice, the CDC is
announcing its intention to seek OMB
clearance to continue a Zika-related
information collections a call center in
CDC’s Emergency Operations Center
(EOC) to respond to inquiries on clinical
care of persons potentially of interest for
Zika virus infection beyond its current
emergency expiration date [OMB
Control No. 0920–1101, expiration date
8/31/16]. Respondents to this
information collection include the
general public, clinicians, and
employees at STLT health departments.
E:\FR\FM\09AUN1.SGM
09AUN1
52695
Federal Register / Vol. 81, No. 153 / Tuesday, August 9, 2016 / Notices
The purpose of this information
collection is to document and track
clinical inquiries made to the CDC EOC
call center and to systematically collect
standardized clinical/demographic/
epidemiological information about
suspected cases. The emergency
clearance for this information collection
dealt specifically with Zika-related
clinical inquiries. However, the new ICR
will cover this project for any EOC
activation. Regardless of the disease or
hazard being responded to, the EOC
operates this call center to answer and
respond to clinical inquiries. This
information collection is a necessary
part of operating this call center and
responding to emergency situations.
These information collections will
align with their legislative authority,
Section 301 of the Public Health Service
Act (42 U.S.C. 241). There are no total
costs to the respondents other than their
time. The total annualized burden
requested is 305 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
State and Local Health Departments .............
Clinicians and Other Providers .......................
Clinical Inquiries Database ............................
Clinical Inquiries Database ............................
Jeffrey M. Zirger,
Health Scientist, Acting Chief, Information
Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for
Science, Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2016–18837 Filed 8–8–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–2147]
General and Plastic Surgery Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting,
Establishment of a Public Docket,
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice, establishment of a
public docket, request for comments.
ACTION:
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the General and Plastic
Surgery Devices Panel of the Medical
Devices Advisory Committee. The
general function of the committee is to
provide advice and recommendations to
the Agency on FDA’s regulatory issues.
The meeting will be open to the public.
FDA is establishing a docket for public
comment on this document.
DATES: The meeting will be held on
September 20 and 21, 2016, from 8 a.m.
to 6 p.m.
ADDRESSES: Hilton Washington, DC
North/Gaithersburg, Grand Ballroom,
620 Perry Pkwy., Gaithersburg, MD
20877. The hotel’s telephone number is
301–977–8900. Answers to commonly
asked questions including information
regarding special accommodations due
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:00 Aug 08, 2016
Jkt 238001
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
You may submit comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
420
800
Number of
responses per
respondent
1
1
Average
burden per
response
(in hrs.)
15/60
15/60
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–2147 for ‘‘General and Plastic
Surgery Devices Panel of the Medical
Devices Advisory Committee; Notice of
Meeting; Establishment of a Public
Docket; Request for Comments.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
E:\FR\FM\09AUN1.SGM
09AUN1
Agencies
[Federal Register Volume 81, Number 153 (Tuesday, August 9, 2016)]
[Notices]
[Pages 52694-52695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18837]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-16AFR]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
Emergency Operations Center (EOC) Clinical Inquiries Database--New--
Office of Public Health Preparedness and Response (OPHPR), Centers for
Disease Control and Prevention (CDC)
Background and Brief Description
In May 2015, the Pan American Health Organization (PAHO) issued an
alert regarding the first confirmed Zika virus infections in Brazil.
Since then, CDC has been responding to increased reports of Zika and
has assisted in investigations with PAHO and the Brazil Ministry of
Health. The first regional travel notices for Zika in South America and
Mexico were posted in December 2015. In December 2015, the Commonwealth
of Puerto Rico, a United States territory, reported its first confirmed
locally transmitted Zika virus case. Cases of local transmission have
recently been confirmed in two other U.S. territories, the United
States Virgin Islands and American Samoa. As of April 6, 2016, U.S.
territories had reported 351 locally acquired Zika cases and 3 travel-
associated Zika cases to CDC. Of the 354 cases reported, 37 were in
pregnant women. Zika has not been spread by mosquitoes in the
continental United States. However, lab tests have confirmed Zika virus
in travelers returning to the United States. These travelers have
gotten the virus from mosquito bites and a few non-travelers got Zika
through sex. With the recent outbreaks in the Americas, the number of
Zika cases among travelers visiting or returning to the United States
is increasing. CDC monitors and reports to the public cases of Zika,
which will help improve our understanding of how and where Zika is
spreading.
Zika virus is spread to people primarily through the bite of an
infected Aedes species mosquito (A. aegypti and A. albopictus).
Mosquitoes that spread Zika virus are aggressive daytime biters, but
they can also bite at night. A pregnant woman can pass Zika virus to
her fetus during pregnancy. CDC is studying how Zika affects
pregnancies. Zika is linked to microcephaly, a severe birth defect that
is a sign of incomplete brain development. Microcephaly is a condition
where a baby's head is much smaller than expected. During pregnancy, a
baby's head grows because the baby's brain grows. Microcephaly can
occur because a baby's brain has not developed properly during
pregnancy or has stopped growing after birth.
In February and March 2016, CDC used OMB emergency clearance
procedures to initiate and expedite multiple urgently needed
information collections in American Samoa, Puerto Rico, Brazil, and
domestically within state, tribal, local, and territorial (STLT)
jurisdictions. These procedures have allowed the agency to target and
refine public health interventions to arrest ongoing spread of
infection.
With this notice, the CDC is announcing its intention to seek OMB
clearance to continue a Zika-related information collections a call
center in CDC's Emergency Operations Center (EOC) to respond to
inquiries on clinical care of persons potentially of interest for Zika
virus infection beyond its current emergency expiration date [OMB
Control No. 0920-1101, expiration date 8/31/16]. Respondents to this
information collection include the general public, clinicians, and
employees at STLT health departments.
[[Page 52695]]
The purpose of this information collection is to document and track
clinical inquiries made to the CDC EOC call center and to
systematically collect standardized clinical/demographic/
epidemiological information about suspected cases. The emergency
clearance for this information collection dealt specifically with Zika-
related clinical inquiries. However, the new ICR will cover this
project for any EOC activation. Regardless of the disease or hazard
being responded to, the EOC operates this call center to answer and
respond to clinical inquiries. This information collection is a
necessary part of operating this call center and responding to
emergency situations.
These information collections will align with their legislative
authority, Section 301 of the Public Health Service Act (42 U.S.C.
241). There are no total costs to the respondents other than their
time. The total annualized burden requested is 305 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hrs.)
----------------------------------------------------------------------------------------------------------------
State and Local Health Departments.... Clinical Inquiries 420 1 15/60
Database.
Clinicians and Other Providers........ Clinical Inquiries 800 1 15/60
Database.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Health Scientist, Acting Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the Associate Director for
Science, Office of the Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016-18837 Filed 8-8-16; 8:45 am]
BILLING CODE 4163-18-P